By 2024, the size of the worldwide Glycobiology Market is expected to reach US$ 1,670.3 million. Glycobiology sales are anticipated to grow at a strong 12.5% CAGR between 2024 and 2034. It is projected that the market for glycobiology will be worth US$5,435.4 million by 2034.
Improvements in the technology of glycobiology instruments are one of the main factors driving the global glycobiology market. The government's increased financing for research as well as the emphasis that biotechnology and pharmaceutical companies are placing on developing novel medications are driving growth in the glycobiology sector. Glycobiology research investigations are receiving more attention, which is another element fueling the market rise.
Get Free Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=Srep_id=9286
Research in glycobiology frequently requires advanced methods and tools, which raises the expense of research and development. The financial barrier constrains the quantity of research studies and inventions in the glycobiology industry. The need for established techniques for glycan analysis causes inconsistent and variable study results. The absence of standardization makes it difficult for researchers to collaborate and impedes the advancement of the discipline.
Regional Outlook
Asia Pacific is experiencing a surge in demand for glycobiology research due to rising healthcare expenditures and increased awareness of personalized treatment. Government programs encouraging research and development have boosted the glycobiology market in Europe and fostered an atmosphere favorable to commercial and academic cooperation. A greater awareness of glycan structures promotes innovation in drug discovery in North America's thriving glycobiology business, aided by pharmaceutical industry strategic alliances.
“Growing research into the functions of complex carbohydrate structures in health and illness stimulates the optimistic glycobiology market expansion. The rising need for treatments and diagnostics highlights a dynamic industry with plenty of room for innovation and global market expansion of glycobiology.” Opines an analyst
Key Companies Profiled in This Report
- Glycodiag
- Tracxn Technologies Limited
- Agilent Technologies, Inc.
- Takara Bio Inc.
- Bio-Techne
- Bruker Corporation
- Thermo Fisher Scientific Inc.
- Shimadzu Corporation
- New England Biolabs.
- co.
- Merck KGaA
- Palleon Pharmaceuticals
- Asparia Glycomics
- RayBiotech Life, Inc.
- Z Biotech, LLC.
- Chemily Glycoscience
- Lectenz Bio
- 2BScientific
Key Takeaways
North America glycobiology market is anticipated to surge at a CAGR of 12.3% by 2024.
Western Europe glycobiology industry to develop at a CAGR of 11.7% through 2024.
The enzymes segment in the product category to grab a share of 54.1% by 2034.
The biopharmaceutical companies’ segment in the end-user category to grab a share of 30.5% by 2034.
In the application category, the drug discovery and development segment to acquire a market share of 58.0% by 2034.
The United States glycobiology market is anticipated to surge at a CAGR of 12.9% by 2034.
Canada glycobiology industry is to develop at a CAGR of 11.6% through 2034.
Germany glycobiology sales are expected to surge at a CAGR of 12.2% until 2034.
Italy glycobiology industry is anticipated to boost at a CAGR of 10.8% by 2034.
France glycobiology sales are to exhibit a CAGR of 11.2% by 2034.
The United Kingdom glycobiology industry is to exhibit a CAGR of 11.9% by 2034.
Competitive Landscape
The market is reasonably competitive, with sizable businesses that substantially contribute to the market expansion for glycobiology. The primary strategies used by the glycobiology vendors for long-term growth include partnerships, collaborations, new product launches, and mergers and acquisitions.
A co-marketing agreement to enhance the application of a mass spectrometry imaging (MSI) platform for spatial multi-omics applications in pharmaceutical and clinical labs was announced in June 2022 by Thermo Fisher Scientific and TransMIT GmbH Center for Mass Spectrometric Developments.
In April 2022, Bruker unveiled a novel MALDI HiPLEX-IHC tissue imaging solution for timsTOF flex, utilizing unbiased lipidomics, glycomics, and metabolomics tissue imaging in combination with HiPLEX-IHC peptide code antibody probes from AmberGen.
Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RCrep_id=9286
Country-wise Analysis
The glycomics market in North America is expected to develop at a 12.7% CAGR through 2034, indicating that it is in a highly favorable growth position. The primary cause of the spike is the rising demand in essential countries, particularly the United States and Canada. The United States is projected to hold a commanding 87.5% of the global glycomics market by 2034.
By 2034, Western Europe expects a significant expansion with a CAGR of 11.3%. Germany is an essential market player in glycobiology, with a notable 25.4% of global glycobiology market share in 2024, highlighting its critical position in the changing environment of the glycomics industry.
Browse Full Report: https://www.factmr.com/report/glycobiology-market
Segmentation of Market Research:
- By Product:
- Enzymes
- Consumables
- Kits and Reagents
- By Application:
- Drug Discovery and Development
- Diagnostic Applications
- Industrial Application
- Therapeutic Application
- Others
- By End User:
- Biopharmaceutical Companies
- Research Laboratories
- Hospitals
- Diagnostic Centers
- Contract Research Organizations
- Biotechnology Industries
- Academic Institutes
- Others
- By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- The Middle East and Africa
Related Publish by Fact.MR Industry:
Patient Lifting Equipment Market
https://www.factmr.com/report/patient-lifting-equipment-market
Near Infrared Imaging Market
https://www.factmr.com/report/near-infrared-imaging-market
Hydrosurgery Systems Market
https://www.factmr.com/report/4706/hydrosurgery-systems-market
Softgel Capsules Market
